Cancer Research

Data on pro-drug as radiation sensitizer presented at cancer research meeting

Published in Cancer Weekly, May 17th, 2005

Spectrum Pharmaceuticals, Inc. (SPPI) announced that data, from a study conducted by Dr. Randy Burd at the Thomas Jefferson University, Philadelphia, Pennsylvania, was presented on EOquin at the 96th Annual Meeting of the American Association for Cancer Research (AACR).

Many tumors grow under conditions of reduced oxygen tension (hypoxia). This makes them insensitive or resistant to treatment by radiation (X-rays). EOquin, a pro-drug, becomes a cytotoxic alkylating agent in the presence of an enzyme that is present in greater amounts in hypoxic cancer cells. In clinical studies conducted to date, EOquin has shown good efficacy in treating patients with refractory...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2005-05-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry